


# Stabilis



## Cefepime dihydrochloride



Noms commerciaux

Aspime	Vénézuela
Avipim	Turquie
Axépipim	France
Baxypime	Mexique
Cachepime	Inde
Cefalospim	Brésil
Cefemin	Colombie
Cefepem	Brésil
Cefepitax	Brésil
Cepim	Italie
Cepimex	Italie
Forcetex	Egypte
Maxcef	Brésil
Maxipime	Allemagne, Autriche, Belgique, Canada, Colombie, Espagne, Etats Unis d'Amérique, Finlande, Grèce, Hongrie, Italie, Luxembourg, Pérou, Pologne, Portugal, Suède, Turquie
Nebamix	Pérou
Olpelinol	Mexique
Pimcef	Pérou
Pimerzen	Mexique
Roxipime	Turquie
Unisef	Turquie
Vipefime	Mexique



### Stabilité des solutions

PVC			2,5/5/10/20 mg/ml	4°C		7			1605
PVC			20 mg/ml	22°C-24°C		3			1605
PVC			20 mg/ml	25°C		2			873
PVC			20 mg/ml	5°C		23			873
PVC			10 mg/ml	22°C-24°C		1			1605
PVC			2,5 mg/ml	22°C-24°C		6			1605

		5 mg/ml	22°C-24°C		3				1605
		10 mg/ml	22°C-24°C		2				1605
		2,5 mg/ml	22°C-24°C		4				1605
		20 mg/ml	-20°C		30				1648
		20 mg/ml	4°C		11				1648
		5 mg/ml	22°C-24°C		1				1605
		0,5 mg/ml	37°C		4				1945
		0,5 mg/ml	4°C		7				1945
		8 mg/ml	24°C		48				1673
		8 mg/ml	4°C		15				1673
		10 mg/ml	23°C		2				1834
		10 mg/ml	4°C		30				1834
		40 mg/ml	23°C		1				1834
		40 mg/ml	4°C		7				1834
		2,9 mg/ml	-20°C		14				2046
		2,9 mg/ml	25°C		24				2046
		2,9 mg/ml	4°C		7				2046
		100 & 200 mg/ml	-20°C		90				1068
		100 & 200 mg/ml	22-24°C		2				1046
		100 & 200 mg/ml	4°C		7				1068
		100 & 200 mg/ml	4°C		14				1046
		100 & 200 mg/ml	-20°C		90				1068
		100 & 200 mg/ml	4°C		7				1068
		125 mg/ml	20-25°C		24				4634
		200 mg/ml	22-24°C		2				1046
		200 mg/ml	4°C		14				1046
		100 mg/ml	22°C-24°C		2				1046
		120 mg/ml	25°C		10				4326
		20 mg/ml	25°C		2				1626
		20 mg/ml	25°C		12				4326
		20 mg/ml	5°C		21				1626
		40 mg/ml	25°C		10				4326
		100 mg/ml	22°C-24°C		1				1046

		50 mg/ml	25°C		20			2042
		50 mg/ml	37°C		13			2042
		0,1 mg/ml	25°C		7			1290
		0,1 mg/ml	37°C		48			1290
		0,1 mg/ml	4°C		14			1290



## Stabilité en mélange

PVC		2,5 & 20 mg/ml	22°C-24°C		Metronidazole : 5 mg/ml	2		1605
PVC		5 mg/ml	22°C-24°C		Metronidazole : 5 mg/ml	4		1605
PVC		10 mg/ml	22°C-24°C		Metronidazole : 5 mg/ml	5		1605
PVC		2,5 >> 20 mg/ml	4°C		Metronidazole : 5 mg/ml	7		1605



## Facteur influençant la stabilité

				2046 2141
	4 < pH < 6			2134



## Compatibilités

	Cefepime dihydrochloride Amikacin sulfate	3549
	Cefepime dihydrochloride : 40 mg/ml Amikacin sulfate : 6 mg/ml	3548
	Cefepime dihydrochloride : 125 mg/ml Amikacin sulfate : 15 mg/ml	2141
	Cefepime dihydrochloride Aminophylline	3548
	Cefepime dihydrochloride : 20 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	921
	Cefepime dihydrochloride : 40 mg/ml Ampicillin sodium : 10 mg/ml	3548
	Cefepime dihydrochloride : 40 mg/ml Ampicillin sodium : 10 mg/ml	3548
	Cefepime dihydrochloride : 4 mg/ml Ampicillin sodium : 40 mg/ml	3548

		Cefepime dihydrochloride : 40 mg/ml Ampicillin sodium : 1 mg/ml		3548
		Cefepime dihydrochloride : 40 mg/ml Ampicillin sodium : 1 mg/ml		3548
		Cefepime dihydrochloride : 20 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Cefepime dihydrochloride : 20 mg/ml Bivalirudin : 5 mg/ml		1713
		Cefepime dihydrochloride : 20 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Cefepime dihydrochloride : 40 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	 	4528
		Cefepime dihydrochloride : 40 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml	 	3828
		Cefepime dihydrochloride : 4 & 40 mg/ml Clindamycin phosphate : 0,25 & 6 mg/ml	 	3548
		Cefepime dihydrochloride : 83.3 mg/ml Daptomycin : 21 mg/ml	 	4254
		Cefepime dihydrochloride : 20 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Cefepime dihydrochloride : 125 mg/ml Dobutamine hydrochloride : 1 mg/ml		2141
		Cefepime dihydrochloride : 20 mg/ml Docetaxel : 0.9 mg/ml		1754
		Cefepime dihydrochloride : 125 mg/ml Dopamine hydrochloride : 0.4 mg/ml		2141
		Cefepime dihydrochloride : 20 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Cefepime dihydrochloride : 40 mg/ml Eravacycline : 0,6 mg/ml		4434
		Cefepime dihydrochloride : 125 mg/ml Erythromycin lactobionate : 5 mg/ml		2141
		Cefepime dihydrochloride Erythromycin lactobionate		3674
		Cefepime dihydrochloride : 40 mg/ml Esmolol hydrochloride : 10 mg/ml		3879
		Cefepime dihydrochloride : 20 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Cefepime dihydrochloride : 20 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Cefepime dihydrochloride : 125 mg/ml Fluconazole : 2 mg/ml		2141
		Cefepime dihydrochloride Gentamicin sulfate		3643
		Cefepime dihydrochloride Gentamicin sulfate		3548
		Cefepime dihydrochloride : 40 mg/ml Labetalol hydrochloride : 5 mg/ml		3879
		Cefepime dihydrochloride : 20 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Cefepime dihydrochloride : 40 mg/ml Metoprolol tartrate : 0.4 mg/ml		3879

		Cefepime dihydrochloride : 100 mg/ml		3948
		Cefepime dihydrochloride : 10 mg/ml		4440
		Cefepime dihydrochloride : 40 mg/ml Fosfomycin : 30 mg/ml		4055
		Cefepime dihydrochloride Gentamicin sulfate		3520
		Cefepime dihydrochloride : 40 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		4465
		Cefepime dihydrochloride : 100 mg/ml		3948
		Cefepime dihydrochloride : 125 mg/ml Isosorbide dinitrate : 0.2 mg/ml		2141
		Cefepime dihydrochloride : 40 mg/ml	RL	4411
		Cefepime dihydrochloride : 125 mg/ml Furosemide : 10 mg/ml		2141
		Cefepime dihydrochloride : 125 mg/ml Gentamicin sulfate : 6 mg/ml		2141
		Cefepime dihydrochloride : 20 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Cefepime dihydrochloride : 4 mg/ml Heparin sodium : 10 & 50 UI/ml		3548
		Cefepime dihydrochloride : 20 mg/ml Hetastarch : 60 mg/ml		1721
		Cefepime dihydrochloride : 125 mg/ml Insulin : 100 UI/ml		2141
		Cefepime dihydrochloride : 40 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Cefepime dihydrochloride : 125 mg/ml Ketamine hydrochloride : 10 mg/ml		2141
		Cefepime dihydrochloride Metronidazole		3548
		Cefepime dihydrochloride : 125 mg/ml Midazolam hydrochloride : 5 mg/ml		2141
		Cefepime dihydrochloride : 20 mg/ml Mycophenolate mofetil : 5,9 mg/ml		2192
		Cefepime dihydrochloride : 125 mg/ml N-acetylcysteine : 100 mg/ml		2141
		Cefepime dihydrochloride Netilmicin sulfate		3548
		Cefepime dihydrochloride : 125 mg/ml Nicardipine hydrochloride : 1 mg/ml		2141
		Cefepime dihydrochloride : 125 mg/ml Phenytoin sodium : 50 mg/ml		2141
		Cefepime dihydrochloride : 125 mg/ml Piritramide : 2 mg/ml		2141
		Cefepime dihydrochloride : 40 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Cefepime dihydrochloride : 40 mg/ml Posaconazole : 1,2 mg/ml		4521
		Cefepime dihydrochloride : 4 mg/ml Potassium chloride : 10 & 40 mEq/l		3548

		Cefepime dihydrochloride : 125 mg/ml Propofol : 1 mg/ml		2141
		Cefepime dihydrochloride : 125 mg/ml Remifentaniil hydrochloride : 200 µg/ml		2141
		Cefepime dihydrochloride : 5 mg/ml Sodium citrate : 40 mg/ml		3416
		Cefepime dihydrochloride : 10 mg/ml Sodium citrate : 40 mg/ml		3416
		Cefepime dihydrochloride : 125 mg/ml Sufentanil citrate : 0.005 mg/ml		2141
		Cefepime dihydrochloride : 40 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Cefepime dihydrochloride : 40 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Cefepime dihydrochloride : 40 mg/ml Telavancin hydrochloride : 7.5 mg/ml	<b>RL</b>	3254
		Cefepime dihydrochloride : 40 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Cefepime dihydrochloride : 200 mg/ml Temocilline : 83.33 mg/ml		2231
		Cefepime dihydrochloride : 125 mg/ml Theophylline : 20 mg/ml		2141
		Cefepime dihydrochloride : 4 mg/ml Theophylline : 0,8 mg/ml		3548
		Cefepime dihydrochloride : 83.3 mg/ml Thiamine hydrochloride : 0.2 mg/ml		4254
		Cefepime dihydrochloride Tobramycin sulfate		3548
		Cefepime dihydrochloride : 125 mg/ml Tobramycin sulfate : 6 mg/ml		2141
		Cefepime dihydrochloride : 125 mg/ml Urapidil : 5 mg/ml		2141
		Cefepime dihydrochloride : 125 mg/ml Valproic acid : 100 mg/ml		2141
		Cefepime dihydrochloride : 200 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Cefepime dihydrochloride : 83.33 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Cefepime dihydrochloride Vancomycin hydrochloride		3548
		Cefepime dihydrochloride : 125 mg/ml Vancomycin hydrochloride : 30 mg/ml		2141
		Cefepime dihydrochloride : 20 mg/ml Vancomycin hydrochloride : 4 mg/ml		3542
		Cefepime dihydrochloride : 83.3 mg/ml Voriconazole : 8 mg/ml		4254



## Voie d'administration



## Bibliographie

	Type	Source
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
873	Revue	Das Gupta V, Maswoswe J, Bailey RE. Stability of cefepime hydrochloride dextrose in 5% dextrose injection and 0.9% sodium chloride injection. Int J Pharm Compound 1997 ; 1: 435-436.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1046	Revue	Stewart JT, Maddox FC, Warren FW. Stability of cefepime hydrochloride in polypropylene syringes. Am J Health-Syst Pharm 1999 ; 56: 1134.
1068	Revue	Stewart JT, Warren FW, Maddox FC. Stability of cefepime hydrochloride in polypropylene syringes at -20°C, 4°C and 22-24°C. Am J Health-Syst Pharm 1999 ; 56: 457-459.
1290	Revue	Williamson JC, Volles DF, Lynch PLM, Rogers PD, Haverstick DM. Stability of cefepime in peritoneal dialysis solution. Ann Pharmacotherapy 1999 ; 33: 906-909.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1605	Revue	Stewart JT, Maddox FC, Warren FW. Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C. Hosp Pharm 2000 ; 35: 1057-1064.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1626	Revue	Ling J, Das Gupta V. Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2001 ; 5: 151-152.
1648	Revue	Schlessor V, Hecq J-D, Vanbeckbergen D, Jamart J, Galanti LM. Effect of freezing, long-term storage, and microwave thawing on the stability of cefepime in 5% dextrose infusion polyvinyl chloride bags. Int J Pharm Compound 2002 ; 6: 391-394.


1673	Revue	Rabouan-Guyon M, Guet AF, Courtois PY, Barthes DMC. Stability study of cefepime in different infusion solutions. Int J Pharm 1997 ; 154: 185-190.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1834	Revue	Trissel LA, Xu QA. Stability of cefepime hydrochloride in autodose infusion system bags. Ann Pharmacotherapy 2003 ; 37, 6: 804-807.
1945	Revue	Elwell RJ, Volino LR, Frye RF. Stability of cefepime in icodextrin peritoneal dialysis solution. Ann Pharmacotherapy 2004 ; 38: 2041-2044.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2042	Revue	Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal $\beta$ -lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2046	Revue	Sprauten PF, Beringer PM, Louie ST, Synold TW, Gill MA. Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother 2003 ; 47: 1991-1994.
2134	Revue	Fubara JO, Notari RE. Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions. J Pharm Sci 1998 ; 87, 12: 1572-1576.
2141	Revue	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2192	Revue	Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.




2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3416	Revue	Csaba M, Boddu,S.H.S , Churchwell M.D. Physical compatibility of sodium citrate with alcohol and cefepime. Am J Health-Syst Pharm 2013 ; 70: 932-937
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011
3542	Revue	Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion Am J Health-Syst Pharm 2015 ; 72:390-395
3548	Laboratoire	Cefepime (Maxipime®) - Summary of Product characteristics. Bristol Myers Squibb 2007
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuconazole sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Revue	Foushee Jaime A, Meredith Pmichalee, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomicin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254	Revue	D&#39;Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4326	Revue	Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P. Stability studies of antipyricyanic beta-lactam antibiotics used in continuous infusion. Pharmazie 2019 ; 74: 357-362.

4411	Revue	Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions. Int J Pharm Compound 2020 ;24,3:238-241.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	Revue	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4465	Revue	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4521	Revue	Polo C, D'Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4634	Revue	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

# Stabilis



## Cefepime dihydrochloride



### Stabilité des préparations

?		1,725 g Maxipime®	Eau ppi 98,3 g	4°C		24		3182
?		1,725 g Maxipime®	Tampon citrate pH 6.25 - 302 mOsmol/L	4°C		27		3182
?		1,725 g Maxipime®	Borate de phenylmercure 0,04% 2,5 g βphenylethylalcool 0,4 g	4°C		27		3182
?		1,725 g Maxipime®	Alcool polyvinylique η=42.3 mPa.s pH 4.4 Tampon citrate pH 6.05 - 586 mOsmol/L	4°C		13,2 g		3182
?		1,725 g Maxipime®	Alcool polyvinylique η=42.3 mPa.s pH 4.4 Borate de phenylmercure 0,04% 2,5 g βphenylethylalcool 0,4 g Tampon citrate pH 6.05 - 586 mOsmol/L	4°C		70 g 21		3182



### Facteur influençant la stabilité

	20°C			3182
--	------	--	--	------


































### Bibliographie

	Type	Source
3182	Revue	Kodym A, PawLowska M, Ruminski JK, Bartosinska A, Kieliba A. Stability of cefepime in eye drops. Pharmazie 2011 ; 66, 1: 17-23.



# Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 Lumière
 Jour	 Non précisée
 A l'abri de la lumière	 Chlorure de sodium 0,9%
 Glucose 5%	 Extraneal® (Baxter)
 Heure	 Polyéthylène
 Ethylène vinyl acétate	 Seringue polypropylène
 Eau pour préparation injectable	 □ Elastomère (non précisé)
 Non précisé	 Deflex® PD 1.5% glucose (Fresenius)
 Stabilité en mélange	 Solvant
 Molécule	 Aucun
 Facteur influençant la stabilité	 Augmentation
 Provoque	 Dégradation
 Augmentation stabilité	 Compatibilités
 Instabilité chimique	 Incompatible
 Compatible	 Incompatibilité non précisée
 Précipitation immédiate	 Turbidité immédiate
 Turbidité en 4 heures	 Changement de couleur après 1 heure
 Nutrition parentérale (mélange binaire)	 Nutrition parentérale (mélange ternaire)
<b>RL</b> Ringer lactate	 Solvant spécifique
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Intramusculaire
 Sous cutanée	 Perfusion sous-cutanée
 Bibliographie	 Collyre

	Stabilité des préparations		Origine
	Excipient		Spécialité pharmaceutique
	Diminution de la stabilité		Dictionnaire